Global Nocturia Market Growth (Status and Outlook) 2025-2031

The global Nocturia market size is predicted to grow from US$ 2787 million in 2025 to US$ 3957 million in 2031; it is expected to grow at a CAGR of 6.0% from 2025 to 2031.

Nocturia, also known as nocturnal polyuria, is a medical condition in which patients get a frequent urge to urinate while sleeping at night. It is particularly prevalent among the elderly who often find it difficult to sleep properly. The three broad categories of nocturia are mixed nocturia, bladder storage problems, and nocturnal polyuria.

The global nocturia market, focused on the treatment of nighttime urination, is growing due to an increasing aging population, rising awareness of urinary disorders, and advancements in treatment options. Below are some key trends driving the market:

1. Growing Aging Population

Primary Driver: Nocturia is more prevalent among the elderly, and with a rapidly aging global population, the demand for nocturia treatments is rising. Regions with older populations, such as Europe, North America, and Japan, are seeing increased incidence rates.

Impact: The increase in elderly individuals with nocturia-related issues is expected to drive the demand for pharmaceutical treatments and non-pharmaceutical interventions.

2. Advancements in Treatment Options

Medications: A range of medications, including anticholinergics, desmopressin, and beta-3 adrenergic receptor agonists, are commonly used to treat nocturia. New drug formulations are being developed to reduce side effects and improve efficacy.

Emerging Therapies: Research into gene therapies and targeted molecular therapies is advancing. Additionally, the combination of medications for better symptom control is being explored.

Non-Pharmacological Treatments: Beyond drugs, lifestyle interventions, such as fluid management, bladder training, and devices like bedwetting alarms, are gaining attention as complementary treatments.

3. Increasing Awareness and Diagnosis

Education: Public health campaigns and awareness programs about nocturia are encouraging individuals to seek medical help. Increased awareness is expected to drive the market as more people seek treatment for the condition.

Early Diagnosis: Enhanced diagnostic tools, including better urodynamic testing and digital health platforms for symptom tracking, are improving early detection and management of nocturia.

4. Regional Growth

North America: The U.S. holds the largest market share due to its advanced healthcare infrastructure, higher awareness, and the presence of major pharmaceutical companies. Increasing cases of nocturia among older adults are a significant market driver.

Europe: Aging populations, particularly in Western Europe, are contributing to the increased demand for nocturia treatments. The market in this region benefits from well-established healthcare systems.

Asia-Pacific: The growing healthcare infrastructure in countries like China, Japan, and India is expected to boost market growth. Rising healthcare expenditure and increasing elderly populations in these regions are key factors.

Global core nocturia manufactures include Astellas Pharma, Allergan, Eli Lilly etc. The top 2 companies hold a share about 30%. North America is the largest market, with a share about 40%, followed by Europe and Asia Pacific with the share about 34% and 18%. In terms of product, alpha blockers is the largest segment, with a share over 37%.

LPI (LP Information)' newest research report, the “Nocturia Industry Forecast” looks at past sales and reviews total world Nocturia sales in 2024, providing a comprehensive analysis by region and market sector of projected Nocturia sales for 2025 through 2031. With Nocturia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nocturia industry.

This Insight Report provides a comprehensive analysis of the global Nocturia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nocturia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nocturia market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nocturia and breaks down the forecast by Type, by Sale Channels, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nocturia.

This report presents a comprehensive overview, market shares, and growth opportunities of Nocturia market by product type, application, key players and key regions and countries.

Segmentation by Type:

Desmopressin

Anticholinergic Drugs

Alpha Blockers

Diuretics

Others

Segmentation by Sale Channels:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Astellas Pharma

Allergan

Ferring Pharmaceuticals

Eli Lilly

GlaxoSmithKline

Sanofi

Pfizer

Abbott

Teva

Mylan

Novartis

Johnson & Johnson

Merck

Astra Zeneca

Bristol-Myers Squibb

Hainan Zhonghe Pharmaceutical

Fosun Pharma

Hybio Pharmaceutical

Rechon Life Science AB

Zhejiang Conba Pharmaceutical

Chengdu Leer Pharmaceutical

Nanjing Xingyin Pharmaceutical Group

Sun Pharmaceutical Industries Ltd.

APOTEX INC

Sagent Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.